Deutsche Tageszeitung - AU to push renewal of US AIDS plan: Africa CDC boss

AU to push renewal of US AIDS plan: Africa CDC boss


AU to push renewal of US AIDS plan: Africa CDC boss
AU to push renewal of US AIDS plan: Africa CDC boss / Photo: © AFP

The African Union's health watchdog said on Sunday the continent's leaders will "send a strong message" for the renewal of the main US programme aimed at reducing the spread of HIV/AIDS.

Change text size:

Launched in 2003, the President's Emergency Plan for AIDS Relief, or PEPFAR, is a major funder of HIV testing, counselling and life-saving treatment worldwide.

The programme until recently has enjoyed near universal support in the US Congress.

But lawmakers have failed formally to renew the scheme for another five years due to the hot-button US issue of abortion.

African leaders "will send a strong message for the re-authorisation of PEPFAR", said Jean Kaseya, head of the Africa Centres for Disease Control and Prevention (Africa CDC).

"We need to accelerate this agenda. Statistics are showing us that everyday young people are affected," he told reporters on the sidelines of the AU summit in Addis Ababa.

"Losing our young people means killing our economy and stopping our development."

The programme, launched by former US president George W. Bush, contributes $16 billion each year for Africa's anti-AIDS response, Kaseya said.

It has been credited with saving millions of lives but health advocates worry that cutting back aid is putting those gains at risk.

The United Nations says the HIV prevention response is 90 percent short of the amount needed by 2025.

As of 2022, there are 39 million people around the world living with HIV, according to the UN AIDS agency. Of them, 20.8 million are in eastern and southern Africa.

But out of the 39 million, 9.2 million do not have access to life-saving treatment. Those missing out include more than 600,000 children.

The UN first set out in 2015 the target of ending AIDS as a public health threat by 2030.

Kaseya said Africa was still on course to achieve that target, adding that the continent would organise a summit later this year to discuss funding.

"We are committed to this agenda and will do our best," he said.

Without re-authorisation, PEPFAR will not automatically end, with funding still in the pipeline, but supporters say that health providers and other donor nations need assurances on long-term US commitment.

(W.Budayev--DTZ)

Featured

RCSI President Calls for Enhanced Surgical Research Support at Millin Meeting

Professor Michael Kerin, president of the Royal College of Surgeons in Ireland (RCSI), has called for increased support for surgeons to strengthen the nation's surgical research capacity. His remarks preceded the annual Millin Meeting, a gathering of leading healthcare experts focused on integrating innovation and clinical trials into everyday surgical practice.

Toddler Diagnosed With Leukemia After Symptoms Dismissed as Winter Illness

Manraj Singh Hans, now seven, was diagnosed with acute lymphoblastic leukemia in February 2023 after a prolonged period during which his early symptoms were repeatedly misdiagnosed as common infections. His parents, Narinder Singh and Parm Hans, initially dismissed signs of illness as winter fatigue before blood in the child’s diaper prompted urgent medical intervention.

American Airlines passenger falls ill and vomits on three travellers

A passenger on board an American Airlines reportedly experienced a medical episode mid-flight A morning flight from Philadelphia to Miami was thrown into disarray after a passenger reportedly vomited over three other travellers.

iPS Cell Research Accelerates Drug Discovery for ALS and Spinal Cord Injury

Researchers at Keiō University are leveraging induced pluripotent stem (iPS) cells to accelerate drug discovery for rare neurological conditions. Director Okano Hideyuki reports that human-derived cell models have enabled the rapid identification of potential treatments for amyotrophic lateral sclerosis and paved the way for regenerative therapies targeting spinal cord injuries.

Change text size: